多发性骨髓瘤的发病机制及药物治疗进展

Progression in the pathogenesis and drug treatment of multiple myeloma

多发性骨髓瘤(mu ltip le myelom a,MM)是一种恶性增殖性疾病,其发病机制十分复杂,近年集中在早期遗传学异常、造血微环境与骨髓瘤细胞的相互作用、NF-κB和Notch信号通路、MM耐药机制几方面,形成了以针对信号通路和骨髓微环境治疗为主的综合治疗框架。一些有前景的药物如沙利度胺、蛋白酶体抑制剂、砷剂等的应用使MM的治疗得到了极大的突破。

Multiple myeloma （MM） is a malignant proliferative disease It＇s pathogenesis is comparatively complicated and recently is focused on abnormality in early：genetics, interaction between hemopoietic microenvironment and myeloma cells, NF-κB and Notch signal pathways and drug resistance. Correspondingly emphases of combined therapies are aimed directly at,signal pathways and bone marrow microenvironment. Applications of several perspective drugs such as Thalidomide, proteasomes inhibitor, arsenical and other agents bring galactic breakthrough to the treatments of MM.